Origin Therapeutics will begin trading on the CSE under the symbol “ORIG”

Origin Therapeutics Holdings Inc.

The Company will begin trading on June 6, 2022 under the symbol “ORIG” on the Canadian Securities Exchange

Vancouver, BC, June 02, 2022 (GLOBE NEWSWIRE) — Origin Therapeutics Holdings Inc. (there “Company” Where “Original therapy”), an actively managed investment issuer focused on the psychedelics industry, is pleased to announce that it has received approval to list its common stock on the Canadian Securities Exchange (the “CSE“). The common shares will begin trading under the symbol “ORIGon June 6, 2022.

“The psychedelics industry has the potential to be very disruptive,” said Alexander Somjen, CEO of Origin Therapeutics. “We created Origin Therapeutics to give retail investors access to a diverse portfolio of high-growth, vetted companies that we believe lead the industry, many of which are not yet publicly traded and would therefore not be accessible to retail investors.”

Origin Therapeutics is led by an experienced team that actively manages its investments through board representation and/or advisory roles to support their growth and success. The Company’s portfolio currently includes:

  • Dimensions Health Centers Inc. (wellness retreats)

  • Xpira Pharmaceuticals Inc. (drug discovery)

  • MicroDose Psychedelic Insights (media and entertainment)

  • Tripsitter Clinic Corp. (medical clinics)

  • Ocean Bio Ltd. (drug discovery)

“We evaluate the companies we invest in based on the caliber of their founders and management team, market opportunities and business model,” Somjen added. “We are continuously conducting industry analysis and evaluating new companies in the sector and will continue to evaluate opportunities while driving the success of our current portfolio.”

For further information regarding the Company and its activities, please consult the detailed prospectus dated 11 May 2022 (the “Prospectus”) accompanying its application for listing on the CSE. A copy of the Prospectus has been filed under the Company’s profile at www.sedar.com.

As part of the CSE listing, the Company also announces that 3,000,000 incentive stock options (the “Options”) were granted on June 6, 2022 to certain directors, officers and consultants of the Company in accordance with the Company’s incentive stock option plan. (the “Option Plan”). The options have an exercise price of $0.25 per share and are exercisable for a period of five years, unless terminated in accordance with the terms of the option plan. The options and all shares issued upon their exercise will be subject to a hold period of four months and one day ending on October 7, 2022. Certain options are subject to escrow conditions, as described in the prospectus.

Sign up to receive updates from Origin Therapeutics at https://originpsychedelics.com/

-##-

About Origin Therapeutics

Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer that focuses on equity investments in companies related to the psychedelics industry in order to provide investors with diversified exposure to the sector. The company, led by a team of industry experts, leverages its management expertise, professional network and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. .

Learn more at www.OriginPsychedelics.com and follow the company on LinkedIn, Twitter and Instagram

For more information:

Alexander Somjen
Chairman and Chief Executive Officer and Director
Origin Therapeutics Holdings Inc.

www.originpsychedelics.com
[email protected]

For media inquiries, please contact: [email protected]

Forward-looking information and statements

Certain statements in this press release regarding the Company are forward-looking statements and are forward-looking in nature. Forward-looking statements are not based on historical fact, but rather on current expectations and projections regarding future events, and are therefore subject to risks and uncertainties that could cause actual results to differ materially. future expressed or implied by the forward-looking statements. statements. These statements can generally be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “will expects, “believes” or “continues”, or the negative thereof or similar variations. Forward-looking statements in this press release include statements regarding the closing of the Offering, the intended use of proceeds of the Offer, the filing of the Prospectus and the obtaining of visas for the Prospectus There are numerous risks and uncertainties which could cause the actual results and the plans and objectives of the Company to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) the risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may have to be used for purposes other than those set out in the present as release and other factors beyond the Company’s control. Actual results and future events could differ materially from those anticipated in this information. This information and all subsequent written and oral forward-looking information is based on management’s estimates and opinions as of the dates it is made and is expressly qualified in its entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved of the contents of this press release and accepts no responsibility for its adequacy or accuracy.

Back To Top